Highlights
- Chimeric Therapeutics has appointed Dr Rebecca McQualter as Chief Operating Officer (COO).
- Dr McQualter brings a diverse commercial background from her time at Novartis, Amgen, and GlaxoSmithKline.
- She is highly skilled in building commercial partnerships and networks with diverse stakeholders.
Chimeric Therapeutics Limited (ASX: CHM), an Australia-based cell therapy company, has named Rebecca McQualter, PhD, as its new COO.
Dr McQualter boasts extensive commercial experience gained from esteemed organisations such as Novartis, Amgen, and GlaxoSmithKline. She holds a Doctor of Philosophy in Cell Therapy and Regenerative Medicine from Monash University.
Seasoned expertise on the board
Before joining Chimeric, Dr McQualter served as Strategic Access Head at Novartis Australia, where she was instrumental in developing commercial partnerships and expanding networks across sectors. Additionally, she collaborated with government bodies and established partnerships with Telstra Health, Monash University, and Wesfarmers Health.
Prior to her tenure at Novartis, Dr McQualter held the role of Country Medical Head at Bioverativ ANZ, AU$5 billion Biogen spinout focusing on rare diseases. Here, she developed business strategies and negotiated with payers, contributing to Bioverativ's acquisition by Sanofi in 2018.
Dr McQualter’s career also includes leadership positions at Amgen, initially in Australia before relocating to the United States to serve as Senior Marketing Manager in Oncology at the Thousand Oaks, California office.
Additionally, she gained experience at GlaxoSmithKline, starting as a Primary Care Sales Representative and advancing to the position of Medical Adviser, where she contributed to two major brand launches.
Reflecting on the appointment, CHM’s Executive Chairman, Paul Hopper, said: "We’re very fortunate to be welcoming Rebecca to Chimeric as we continue to grow and advance our portfolio of transformative cell therapies. She brings an excellent array of experience, including having worked alongside Amgen’s Global Head of Oncology in the US, as well as a commercial focus and dynamic leadership skills that will serve Chimeric well as it pursues its next phase of growth.”
CHM shares traded at AU$0.027 apiece at the time of writing on 10 May 2024.